{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:29:11Z","timestamp":1792186151850,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00404-020-05855-1","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T17:03:14Z","timestamp":1604336594000},"page":"1099-1108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Oxytocin and cabergoline alleviate ovarian hyperstimulation syndrome (OHSS) by suppressing vascular endothelial growth factor (VEGF) in an experimental model"],"prefix":"10.1007","volume":"303","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3833-0999","authenticated-orcid":false,"given":"Ismet","family":"Hortu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Karadadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gokay","family":"Ozceltik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erol","family":"Tavmergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ege Nazan","family":"Tavmergen Goker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurkan","family":"Yigitturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oytun","family":"Erbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"key":"5855_CR1","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1080\/09513590.2019.1592153","volume":"35","author":"AP Petrenko","year":"2019","unstructured":"Petrenko AP, Castelo-Branco C, Marshalov DV, Salov IA, Shifman EM (2019) Ovarian hyperstimulation syndrome. A new look at an old problem. Gynecol Endocrinol 35:651\u2013656","journal-title":"Gynecol Endocrinol"},{"key":"5855_CR2","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1093\/humrep\/dew149","volume":"31","author":"P Humaidan","year":"2016","unstructured":"Humaidan P, Nelson SM, Devroey P, Coddington CC, Schwartz LB, Gordon K et al (2016) Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials. Hum Reprod 31:1997\u20132004","journal-title":"Hum Reprod"},{"key":"5855_CR3","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.fertnstert.2016.08.048","volume":"106","author":"Practice Committee of the American Society for Reproductive Medicine","year":"2016","unstructured":"Practice Committee of the American Society for Reproductive Medicine (2016) Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril 106:1634\u20131647","journal-title":"Fertil Steril"},{"key":"5855_CR4","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1177\/1933719117697257","volume":"24","author":"E Zohav","year":"2017","unstructured":"Zohav E, Almog B, Cohen A, Levin I, Deutsch V, Many A et al (2017) A New perspective on the risk of hypercoagulopathy in ovarian hyperstimulation syndrome using thromboelastography. Reprod Sci 24:1600\u20131606","journal-title":"Reprod Sci"},{"key":"5855_CR5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/uog.14684","volume":"45","author":"CO Nastri","year":"2015","unstructured":"Nastri CO, Teixeira DM, Moroni RM, Leitao VM, Martins WP (2015) Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention. Ultrasound Obstet Gynecol 45:377\u2013393","journal-title":"Ultrasound Obstet Gynecol"},{"key":"5855_CR6","unstructured":"Taylor HS, Pal L, Seli E (2020) Speroff\u2019s Clinical Gynecologic Endocrinology and Infertility. In: Hugh ST, Lubna P, Emre S (eds) Induction of Ovulation 9th ed. Wolters Kluwer, New York pp 2784-2888"},{"key":"5855_CR7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.fertnstert.2011.12.046","volume":"97","author":"SR Soares","year":"2012","unstructured":"Soares SR (2012) Etiology of OHSS and use of dopamine agonists. Fertil Steril 97:517\u2013522","journal-title":"Fertil Steril"},{"key":"5855_CR8","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1210\/jc.2011-0075","volume":"96","author":"R G\u00f3mez","year":"2011","unstructured":"G\u00f3mez R, Ferrero H, Delgado-Rosas F, Gaytan M, Morales C, Zimmermenn RC et al (2011) Evidences for the existence of a low dopaminergic tone in polycystic ovarian syndrome: implications for OHSS development and treatment. J Clin Endocrinol Metab 96:2484\u20132492","journal-title":"J Clin Endocrinol Metab"},{"key":"5855_CR9","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/humupd\/dmn008","volume":"14","author":"SR Soares","year":"2008","unstructured":"Soares SR, G\u00f3mez R, Sim\u00f3n C, Garc\u00eda-Velasco JA, Pellicer A (2008) Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update 14:321\u2013333","journal-title":"Hum Reprod Update"},{"key":"5855_CR10","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1016\/S0049-3848(17)30070-1","volume":"151","author":"SM Nelson","year":"2017","unstructured":"Nelson SM (2017) Prevention and management of ovarian hyperstimulation syndrome. Thromb Res 151:S61\u2013S64","journal-title":"Thromb Res"},{"key":"5855_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13048-014-0106-2","volume":"7","author":"R Orvieto","year":"2014","unstructured":"Orvieto R, Dratvinman-Storobinsky O, Lantsberg D, Haas J, Mashiach R, Cohen Y (2014) Interleukin-2 and SOCS-1 proteins involvement in the pathophysiology of severe ovarian hyperstimulation syndrome\u2013 a preliminary proof of concept. J Ovarian Res 7:106","journal-title":"J Ovarian Res"},{"key":"5855_CR12","first-page":"CD008605","volume":"11","author":"H Tang","year":"2016","unstructured":"Tang H, Mourad S, Zhai SD, Hart RJ (2016) Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 11:CD008605","journal-title":"Cochrane Database Syst Rev"},{"key":"5855_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.20471\/acc.2017.56.01.19","volume":"56","author":"M Kasum","year":"2017","unstructured":"Kasum M, Ore\u015bkovi\u0107 S, Franuli\u0107 D, \u010chei\u0107 E, Lila A, Vuji\u0107 G et al (2017) Current medical strategies in the prevention of ovarian hyperstimulation syndrome. Acta Clin Croat 56:133\u2013142","journal-title":"Acta Clin Croat"},{"key":"5855_CR14","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00404-015-3991-8","volume":"293","author":"V Pergialiotis","year":"2016","unstructured":"Pergialiotis V, Frountzas M, Prodromidou A, Prapa S, Perrea DN, Vlachos GD (2016) Propranolol and oxytocin versus oxytocin alone for induction and augmentation of labor: a meta-analysis of randomized trials. Arch Gynecol Obstet 293:721\u2013729","journal-title":"Arch Gynecol Obstet"},{"key":"5855_CR15","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1111\/j.1755-5949.2010.00185.x","volume":"16","author":"C Viero","year":"2010","unstructured":"Viero C, Shibuya I, Kitamura N, Verkhratsky A, Fujihara H, Katoh A et al (2010) REVIEW: oxytocin: crossing the bridge between basic science and pharmacotherapy. CNS NeurosciTher 16:e138\u2013e156","journal-title":"CNS NeurosciTher"},{"key":"5855_CR16","doi-asserted-by":"publisher","first-page":"4895","DOI":"10.1093\/hmg\/ddq424","volume":"19","author":"F Schaller","year":"2010","unstructured":"Schaller F, Watrin F, Sturny R, Massacrier A, Szepetowski P, Muscatelli F (2010) A single postnatal injection of oxytocin rescues the lethal feeding behaviour in mouse newborns deficient for the imprinted Magel2 gene. Hum Mol Gen 19:4895\u20134905","journal-title":"Hum Mol Gen"},{"key":"5855_CR17","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1515\/jbcpp-2016-0197","volume":"28","author":"MM Ragy","year":"2017","unstructured":"Ragy MM, Aziz NM (2017) Prevention of renal ischemia\/reperfusion-induced renal and hepatic injury in adult male Albino rats by oxytocin: role of nitricoxide. J Basic Clin Physiol Pharmacol 28:615\u2013621","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"5855_CR18","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s00404-020-05534-1","volume":"301","author":"I Hortu","year":"2020","unstructured":"Hortu I, Ozceltik G, Ergenoglu AM, Yigitturk G, Atasoy O, Erbas O (2020) Protective effect of oxytocin on a methotrexate-induced ovarian toxicity model. Arch Gynecol Obstet 301:1317\u20131324","journal-title":"Arch Gynecol Obstet"},{"key":"5855_CR19","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s11596-020-2213-1","volume":"40","author":"I Hortu","year":"2020","unstructured":"Hortu I, Ozceltik G, Karadadas E, Erbas O, Yigitturk G, Ulukus M (2020) The role of ankaferd blood stopper and oxytocin as potential therapeutic agents in endometriosis: a rat model. Curr Med Sci 40:556\u2013562","journal-title":"Curr Med Sci"},{"key":"5855_CR20","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.7150\/jca.23769","volume":"9","author":"H Ji","year":"2018","unstructured":"Ji H, Liu N, Yin Y, Wang X, Chen X, Li J et al (2018) Oxytocininhibitsovariancancermetastasisbyrepressingtheexpression of MMP-2 and VEGF. J Cancer 9:1379\u20131384","journal-title":"J Cancer"},{"key":"5855_CR21","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3109\/09513590.2016.1152575","volume":"32","author":"E Kasap","year":"2016","unstructured":"Kasap E, Turan GA, Eskicio\u011flu F, Cengiz H, Gur EB, Sivrikoz ON et al (2016) Comparison between resveratrol and cabergoline in preventing ovarian hyper stimulation syndrome in a rat model. Gynecol Endocrinol 32:634\u2013640","journal-title":"Gynecol Endocrinol"},{"key":"5855_CR22","doi-asserted-by":"publisher","first-page":"692","DOI":"10.3109\/00016341003592537","volume":"89","author":"A Saylan","year":"2010","unstructured":"Saylan A, Arioz DT, Koken T, Dilek H, Saylan F, Yilmazer M (2010) Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam. Acta Obstet Gynecol Scand 89:692\u2013699","journal-title":"Acta Obstet Gynecol Scand"},{"key":"5855_CR23","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/PL00005227","volume":"357","author":"M Petersson","year":"1998","unstructured":"Petersson M, Lundeberg T, Sohlstrom A, Wiberg U, UvnasMoberg K (1998) Oxytocin increases the survival of musculocutaneous flaps. Naunyn Schmiedebergs Arch Pharmacol 357:701\u2013704","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"5855_CR24","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/j.fertnstert.2014.07.1240","volume":"102","author":"H Ferrero","year":"2014","unstructured":"Ferrero H, Garcia-Pascual CM, Gayt\u00e1n M, Morales C, Sim\u00f3n C, Gayt\u00e1n F et al (2014) Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in an ovarian hyperstimulation syndrome (OHSS) animal model: implications for treatment of OHSS with dopamine receptor 2 agonists. Fertil Steril 102:1468\u20131476","journal-title":"Fertil Steril"},{"key":"5855_CR25","first-page":"CD002811","volume":"5","author":"A D\u2019Angelo","year":"2017","unstructured":"D\u2019Angelo A, Amso NN, Hassan R (2017) Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 5:CD002811","journal-title":"Cochrane Database Syst Rev"},{"key":"5855_CR26","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1177\/1745505716664743","volume":"12","author":"O El Tokhy","year":"2016","unstructured":"El Tokhy O, Kopeika J, El-Toukhy T (2016) An update on the prevention of ovarian hyperstimulation syndrome. Womens Health (Lond) 12:496\u2013503","journal-title":"Womens Health (Lond)"},{"key":"5855_CR27","doi-asserted-by":"publisher","first-page":"19093","DOI":"10.1038\/srep19093","volume":"6","author":"JL Guo","year":"2016","unstructured":"Guo JL, Zhang DD, Zhao Y, Zhang D, Zhang XM, Zhou CQ et al (2016) Pharmacologic interventions in preventing ovarian hyperstimulation syndrome: a systematic review and network meta-analysis. Sci Rep 6:19093","journal-title":"Sci Rep"},{"key":"5855_CR28","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10815-011-9708-4","volume":"29","author":"ES Tehraninejad","year":"2012","unstructured":"Tehraninejad ES, Hafezi M, Arabipoor A, Aziminekoo E, Chehrazi M, Bahmanabadi A (2012) Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. J Assist Reprod Gen 29:259\u2013264","journal-title":"J Assist Reprod Gen"},{"key":"5855_CR29","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12958-015-0102-4","volume":"13","author":"H Ferrero","year":"2015","unstructured":"Ferrero H, Garc\u00eda-Pascual CM, Pellicer N, Sim\u00f3n C, Pellicer A, G\u00f3mez R (2015) Dopamine agonist inhibits vascular endothelial growth factor protein production and secretion in granulosa cells. Reprod Biol Endocrinol 13:104","journal-title":"Reprod Biol Endocrinol"},{"key":"5855_CR30","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1055\/s-0030-1265670","volume":"28","author":"R Gomez","year":"2010","unstructured":"Gomez R, Soares SR, Busso C, Garcia-Velasco JA, Sim\u00f3n C, Pellicer A (2010) Physiology and pathology of ovarian hyperstimulation syndrome. Semin Reprod Med 28:448\u2013457","journal-title":"Semin Reprod Med"},{"key":"5855_CR31","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.repbio.2019.03.005","volume":"19","author":"S Gaafar","year":"2019","unstructured":"Gaafar S, El-Gezary D, El Maghraby HA (2019) Early onset of cabergoline therapy for prophylaxis from ovarian hyperstimulation syndrome (OHSS): a potentially safer and more effective protocol. Reprod Biol 19:145\u2013148","journal-title":"Reprod Biol"},{"key":"5855_CR32","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3109\/09513590.2014.1000849","volume":"31","author":"L Akman","year":"2015","unstructured":"Akman L, Sahin G, Erbas O, Aktug H, Akdogan A, Goker EN et al (2015) Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model. Gynecol Endocrinol 31:369\u2013373","journal-title":"Gynecol Endocrinol"},{"key":"5855_CR33","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s00404-015-3987-4","volume":"293","author":"N \u015eahin","year":"2016","unstructured":"\u015eahin N, Apayd\u0131n N, T\u00f6z E, Sivrikoz ON, Gen\u00e7 M, Turan GA et al (2016) Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome. Arch Gynecol Obstet 293:1101\u20131106","journal-title":"Arch Gynecol Obstet"},{"key":"5855_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20650","volume":"20","author":"Z Alfirevic","year":"2016","unstructured":"Alfirevic Z, Keeney E, Dowswell T, Welton NJ, Medley N, Dias S et al (2016) Which method is the best for the induction of labour? A systematic review, network meta-analysis and cost-effectiveness analysis. HealthTechnol Assess 20:1\u2013584","journal-title":"HealthTechnol Assess"},{"key":"5855_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jb\/mvu031","volume":"156","author":"K Matsumoto","year":"2014","unstructured":"Matsumoto K, Ema M (2014) Roles of VEGF-A signalling in development, regeneration, and tumours. J Biochem 156:1\u201310","journal-title":"J Biochem"},{"key":"5855_CR36","first-page":"1139","volume":"34","author":"M Kasum","year":"2010","unstructured":"Kasum M (2010) New insights in mechanisms for development of ovarian hyperstimulation syndrome. Coll Antropol 34:1139\u20131143","journal-title":"Coll Antropol"},{"key":"5855_CR37","unstructured":"Laurence L. Brunton, John S. Lazo, Keith L. Parker (2006) Goodman & Gillman\u2019s The Pharmacological Basis of Therapeutics. In: Laurence LB, Randa H-D, Bj\u00f6rn CK (eds) Hormones and Hormone Antagonists 11th ed. McGraw-HILL, New York pp 1500."},{"key":"5855_CR38","unstructured":"Laurence L. Brunton, John S. Lazo, Keith L. Parker (2006) Goodman & Gillman\u2019s The Pharmacological Basis of Therapeutics. In: Laurence LB, Randa H-D, Bj\u00f6rn CK (eds) Hormones and Hormone Antagonists 11th ed. McGraw-HILL, New York pp 1508."}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05855-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00404-020-05855-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05855-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T13:04:20Z","timestamp":1616418260000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00404-020-05855-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,2]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["5855"],"URL":"https:\/\/doi.org\/10.1007\/s00404-020-05855-1","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,2]]},"assertion":[{"value":"31 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All the authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present study was approved by the Committee for Animal Research of Ege University, Izmir, Turkey. All procedures performed in studies involving animals were in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The informed consent is not applicable for the current study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}